IL320955A - Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile - Google Patents

Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Info

Publication number
IL320955A
IL320955A IL320955A IL32095525A IL320955A IL 320955 A IL320955 A IL 320955A IL 320955 A IL320955 A IL 320955A IL 32095525 A IL32095525 A IL 32095525A IL 320955 A IL320955 A IL 320955A
Authority
IL
Israel
Prior art keywords
difficile
eliciting
clostridium
methods
immune response
Prior art date
Application number
IL320955A
Other languages
Hebrew (he)
Inventor
Annaliesa Sybil Anderson
Marina A Gonzalez-Garis
Lei Hu
Isis Kanevsky
Paul Arthur Liberator
Justin Keith Moran
Lynn Marie Phelan
Michael William Pride
Shuai Shi
Naveen Surendran
Original Assignee
Pfizer
Annaliesa Sybil Anderson
Gonzalez Garis Marina A
Lei Hu
Isis Kanevsky
Paul Arthur Liberator
Justin Keith Moran
Lynn Marie Phelan
Michael William Pride
Shuai Shi
Naveen Surendran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Annaliesa Sybil Anderson, Gonzalez Garis Marina A, Lei Hu, Isis Kanevsky, Paul Arthur Liberator, Justin Keith Moran, Lynn Marie Phelan, Michael William Pride, Shuai Shi, Naveen Surendran filed Critical Pfizer
Publication of IL320955A publication Critical patent/IL320955A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL320955A 2022-12-13 2023-12-11 Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile IL320955A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263387100P 2022-12-13 2022-12-13
US202363485995P 2023-02-20 2023-02-20
US202363598556P 2023-11-14 2023-11-14
PCT/IB2023/062488 WO2024127215A2 (en) 2022-12-13 2023-12-11 Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Publications (1)

Publication Number Publication Date
IL320955A true IL320955A (en) 2025-07-01

Family

ID=89662086

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320955A IL320955A (en) 2022-12-13 2023-12-11 Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Country Status (12)

Country Link
US (1) US20240189410A1 (en)
EP (1) EP4633669A2 (en)
JP (2) JP7817503B2 (en)
KR (1) KR20250120405A (en)
CN (1) CN120475988A (en)
AU (1) AU2023393199A1 (en)
CO (1) CO2025007834A2 (en)
IL (1) IL320955A (en)
MX (1) MX2025006896A (en)
PE (1) PE20251914A1 (en)
TW (1) TW202438104A (en)
WO (1) WO2024127215A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI909678B (en) * 2023-09-13 2025-12-21 美商輝瑞股份有限公司 Methods for producing an adjuvant
TW202612726A (en) * 2024-06-12 2026-04-01 美商輝瑞股份有限公司 Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US628371A (en) 1898-09-10 1899-07-04 Clark W Thomas Machine for making berry-boxes.
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
EP0092574B1 (en) 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE4321946A1 (en) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonic acid esters, process for their preparation and their use
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DK1187629T3 (en) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
JP2008506789A (en) 2004-07-18 2008-03-06 シーエスエル、リミテッド Immunostimulatory complex and oligonucleotide formulation for inducing enhanced interferon-gamma response
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
KR101329374B1 (en) 2008-12-09 2013-11-14 콜레이 파마시티컬 그룹, 인코포레이티드 Immunostimulatory oligonucleotides
DK2424562T3 (en) 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumococcal vaccine and uses thereof
AR086199A1 (en) 2011-04-22 2013-11-27 Wyeth Llc COMPOSITIONS RELATED TO A MUTANT DIFFICILE CLOSTRIDIUM TOXIN AND ITS METHODS
BR122016023101B1 (en) 2012-10-21 2022-03-22 Pfizer Inc Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile
EP2928489B1 (en) * 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN107124869B (en) * 2014-03-25 2022-04-01 美国政府陆军部 Non-toxic adjuvant formulations comprising a liposomal composition comprising monophosphoryl lipid a (mpla) and a saponin
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
EP3678695A1 (en) * 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
MX2020003756A (en) 2017-09-28 2020-07-29 Pfizer COMPOSITIONS AND METHODS TO OBTAIN AN IMMUNE RESPONSE AGAINST CLOSTRIDIUM DIFFICILE.
WO2020201985A1 (en) 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB2600468A (en) * 2020-10-30 2022-05-04 Excivion Ltd Adjuvant composition
AU2023235562B2 (en) 2022-03-14 2026-07-30 Pfizer Inc. Methods for producing an adjuvant

Also Published As

Publication number Publication date
JP7817503B2 (en) 2026-02-18
AU2023393199A1 (en) 2025-05-29
JP2025541207A (en) 2025-12-18
TW202438104A (en) 2024-10-01
WO2024127215A3 (en) 2024-11-07
JP2026082987A (en) 2026-05-19
MX2025006896A (en) 2025-07-01
WO2024127215A2 (en) 2024-06-20
EP4633669A2 (en) 2025-10-22
CN120475988A (en) 2025-08-12
CO2025007834A2 (en) 2025-06-26
KR20250120405A (en) 2025-08-08
US20240189410A1 (en) 2024-06-13
PE20251914A1 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
EP4458975A3 (en) Hbv vaccines and methods treating hbv
IN2014DN08830A (en)
WO2013006842A3 (en) Self-replicating rna prime - protein boost vaccines
WO2011109833A3 (en) Induced dendritic cell compositions and uses thereof
IL307749A (en) Compositions and method for optimized peptide vaccines using residue optimization
MY202505A (en) Zika vaccines and immunogenic compositions, and methods of using the same
WO2011139769A3 (en) Immunogenic compositions and methods for treating neoplasia
EP4171574A4 (en) Compositions and methods for inducing an immune response against coronavirus
WO2019118974A3 (en) Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MX2020005554A (en) Zika vaccines and immunogenic compositions, and methods of using the same.
CA3276659A1 (en) Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2012174455A3 (en) Group a streptococcus multivalent vaccine
MX2025006896A (en) Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
HK1248541A1 (en) Leptospira immunoprotective proteins and methods of identification and use thereof
EP4247401A4 (en) Compositions and methods for optimized peptide vaccines
ZA202203368B (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof
SG11202106494RA (en) Compositions, methods and uses for eliciting an immune response
NZ704204A (en) Method of providing protective immunity against heterologous leptospira strains
MX2017014666A (en) Methods for immunizing against clostridium difficile.
HK40087478A (en) Immunogenic constructs, compositions, and methods for inducing immune response
ZA201905875B (en) Immunostimulating compositions and uses therefore
EP3852796A4 (en) Vaccine, method of vaccination against clostridium difficile
AU2022903749A0 (en) Components, compositions, and methods for inducing an immune response
PH12022550081A1 (en) Ehrlichia vaccines and immunogenic compositions